Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ACC-001

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
OBJECTIVES Long-term safety and tolerability of ACC-001 (vanutide cridificar), an antiamyloid- beta therapeutic vaccine, was… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2017
2017
Both active and passive anti-β-amyloid (Aβ) immunotherapies have been reported to clear brain Aβ deposits in transgenic mouse… Expand
Is this relevant?
2016
2016
Vanutide cridificar (ACC-001), an immunotherapeutic vaccine, is a potentially disease-modifying therapy that aims to reduce brain… Expand
Is this relevant?
2016
2016
BACKGROUND ACC-001 is an investigational therapeutic vaccine designed to elicit antibodies against the N-terminal peptide 1-7 of… Expand
Is this relevant?
2016
2016
BACKGROUND Vanutide Cridificar (ACC-001), a novel investigational immunotherapeutic vaccine designed to elicit antibodies against… Expand
Is this relevant?
2015
2015
OBJECTIVE Multiple lines of evidence indicate that pathological accumulation of amyloid beta (Aβ) peptide in the brain is linked… Expand
Is this relevant?
Review
2014
Review
2014
Both active and passive anti-β-amyloid (Aβ) immunotherapies for the treatment of Alzheimer's disease (AD) have demonstrated… Expand
Is this relevant?
Review
2014
Review
2014
PURPOSE OF REVIEW We reviewed clinical trials on active and passive anti-β-amyloid (Aβ) immunotherapy for the treatment of… Expand
  • table 1
Is this relevant?
Review
2009
Review
2009
We would like to clarify and update information in the review article by Wilcock and Colton recently published in JAD [1]. In… Expand
Is this relevant?
Review
2008
Review
2008
Background: In a phase 2a clinical trial of AN1792 (Study 201), a potential immunotherapeutic agent for use in Alzheimer’s… Expand
  • table 1
Is this relevant?